Global Regulatory Compliance for Aseptic Barrier Systems

As sterile pharmaceutical manufacturing evolves, isolators and Restricted Access Barrier Systems (RABS) have become central to contamination control strategies across global markets. Yet regulatory expectations from the FDA, EU GMP Annex 1, PIC/S, and WHO differ in meaningful ways, from legal enforceability to technical prescriptiveness, creating compliance complexity for manufacturers supplying multiple markets.

This webinar provides a structured comparison of the four major regulatory frameworks governing aseptic barrier systems, examining where they converge on scientific fundamentals and where they diverge in documentation requirements, monitoring expectations, and treatment of advanced technologies. Special focus will be given to the 2022 revision of EU GMP Annex 1 and its harmonized adoption across PIC/S and WHO.

Attendees will leave with a clearer understanding of how to design and qualify barrier systems that satisfy both the principle-based flexibility of the FDA and the structured minimum standards of the EU/PIC/S/WHO model, supporting a robust, globally acceptable contamination control strategy.

KEY LEARNING OBJECTIVES

– Understand how FDA, EU GMP Annex 1, PIC/S, and WHO align and differ in their requirements for isolators, RABS, and contamination control strategy documentation
– Identify the practical compliance implications of regulatory divergence for manufacturers operating across multiple jurisdictions
– Apply a risk-based framework for barrier system design, decontamination validation, and environmental monitoring that satisfies global inspection expectations